Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Titel:
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Auteur:
Fizazi, Karim Foulon, Stéphanie Carles, Joan Roubaud, Guilhem McDermott, Ray Fléchon, Aude Tombal, Bertrand Supiot, Stéphane Berthold, Dominik Ronchin, Philippe Kacso, Gabriel Gravis, Gwenaëlle Calabro, Fabio Berdah, Jean-François Hasbini, Ali Silva, Marlon Thiery-Vuillemin, Antoine Latorzeff, Igor Mourey, Loïc Laguerre, Brigitte Abadie-Lacourtoisie, Sophie Martin, Etienne El Kouri, Claude Escande, Anne Rosello, Alvar Magne, Nicolas Schlurmann, Friederike Priou, Frank Chand-Fouche, Marie-Eve Freixa, Salvador Villà Jamaluddin, Muhammad Rieger, Isabelle Bossi, Alberto